Clinical and Microbiological Characteristics of Neonates with Candidemia and Impacts of Therapeutic Strategies on the Outcomes

Yu-Ning Chen 1,2, Jen-Fu Hsu 1,2, Shih-Ming Chu 1,2, Mei-Yin Lai 1,2, Chih Lin 2,3,4, Hsuan-Rong Huang 1,2, Peng-Hong Yang 2,5, Ming-Chou Chiang 1,2 and Ming-Horng Tsai 2,6,*

Abstract: Neonatal candidemia is associated with significant morbidities and a high mortality rate. We aimed to investigate the clinical characteristics of Candida bloodstream infections in neonates and the impact of therapeutic strategies on the outcomes. We identified all the neonates with candidemia from a medical center in Taiwan over an 18-year period (2003–2021) and analyzed them. Clinical isolates were confirmed by DNA sequencing, and antifungal susceptibility testing was performed. The prognostic factors associated with clinical treatment failure (30-day, all-cause mortality and persistent candidemia > 72 h after antifungal agents) and in-hospital mortality were analyzed using logistic regression modeling. A total of 123 neonates with 139 episodes of candidemia were included in the study. The median (IQR) gestational age and birth weight of the neonates with candidemia were 29.0 (26.0–35.0) weeks and 1104.0 (762.0–2055) g, respectively. The most common Candida spp. was Candida albicans (n = 57, 41.0%), followed by C. parapsilosis (n = 44, 31.7%), Candida guilliermondii (n = 12, 8.6%), and C. glabrata (n = 11, 7.9%). The overall susceptibility to fluconazole was 81.3%, and the resistant rates against other antifungal agents were less than 3%. The cumulative mortality rate at 7 and 30 days after the first episode of candidemia was 11.3% and 32.3%, respectively. The overall in-hospital mortality rate was 42.3%. The treatment outcomes did not change over the study period and were not affected by delayed initiation of antifungal agents. Multivariate analysis showed that delayed catheter removal (odds ratio [OR], 5.54; 95% confidence interval [CI]: 1.93–15.86, p = 0.001), septic shock (OR, 7.88; 95% CI: 2.83–21.93, p < 0.001), and multiple chronic comorbidities (OR, 8.71; 95% CI: 1.82–41.81, p = 0.007) were independently associated with the final in-hospital mortality. We concluded that the overall mortality of neonatal candidemia has remained consistently high over the past decade. Prompt early catheter removal and an aggressive treatment strategy for neonatal candidemia with septic shock would be critical to improving patient outcomes.

Keywords: candidemia; intensive care unit; antifungal resistance; bloodstream infection; invasive candidiasis

1. Introduction

Bloodstream infections (BSIs) caused by candida species remain a substantial burden in the hospital and are associated with high morbidity and mortality rates among intensive
care unit (ICU) patients [1,2]. Invasive candidiasis or candidemia deserves greater concern because it is associated with a high mortality rate of 35–60%, especially in critically ill neonates [3–5]. Recent population-based surveillance studies have shown an increasing incidence of invasive candidiasis in the neonatal ICU during the past decade [6,7]. An increased survival rate of extremely preterm neonates with long-term hospitalization and the widespread use of broad-spectrum antibiotics may account for the increasing incidence of invasive candidiasis [8–10]. Furthermore, more antifungal prophylaxis and the empiric use of echinocandins are reported to be associated with a continuous shift from *C. albicans* to various non-*albicans* *Candida* candidemia, which are more likely to be azole-resistant [11,12].

There have been numerous studies that describe the epidemiology, clinical features, antifungal treatment, and outcomes of neonates with candidemia [6–10]. However, few researchers have investigated the reasons for the treatment failure of neonatal candidemia [5,12–14]. The effects of the different therapeutic strategies on the final outcomes of candidemia are often concluded from adult patients or studies conducted in the surgical and pediatric ICUs or the hematological wards [2,15,16]. Additionally, the studies of neonatal candidemia were often limited by small sample sizes or lack of antifungal resistance or did not analyze the impact of different therapeutic strategies on outcome [2,6–10,13–16]. The aims of this study were to describe the clinical characteristics of neonates with candidemia, to present the results of antifungal susceptibility testing, and to assess the influences of different therapeutic strategies on the outcomes.

2. Patients and Methods

2.1. Study Population, Setting, and Design

All the hospitalized neonates admitted to the NICU of Linkou Chang Gung Memorial Hospital (CGMH) from January 2003 through December 2020 with documented candidemia were enrolled for analysis. Candidemia was defined as being present in those with ≥1 blood culture positive for *Candida* species and who had symptoms and signs compatible with *Candida* BSI [2,7,15]. Episodes were considered to be separate if they occurred ≥1 month apart [17,18]. Catheter-related *Candida* BSI was diagnosed when the catheter tip culture was positive for the same *Candida* species as those obtained from the peripheral vein and there was no evidence of infection at another site [19]. Persistent candidemia was defined as a positive blood culture of candida species for >5 days [20]. The severity of illness was measured by the Neonatal Therapeutic Intervention Scoring System (NTISS) score on the day of candidemia [21], and the presence of severe sepsis or septic shock at presentation was defined based on the standard criteria [22].

The primary study outcome was clinical treatment failure, which was defined according to the Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria [23], as the following: (1) all-cause mortality between days 3 and 30 from the initial positive blood culture or (2) persistent fungal BSI for ≥72 h after the initiation of antifungal therapy. Patients who died within the first 72 h were excluded from the analysis of outcome predictors to ensure that the potential impact of therapeutic strategies could be appropriately investigated. The secondary outcome of in-hospital, all-cause mortality was also analyzed.
2.3. Microbiological Studies

All Candida isolates were processed to have species re-identification using Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF, Bruker Biotype, software version 3.0, San Jose, CA, USA) and molecular methodology by sequencing the internal transcribed spacer regions (ITS1 and ITS2) from ribosomal DNA. Therefore, the identities of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis isolates were confirmed. The in vitro antifungal susceptibilities of the isolates were evaluated according to the EUCAST-Antifungal Susceptibility Testing microdilution method [24,25]. Candida krusei ATCC®® 6258 and Candida parapsilosis ATCC®® 22,019 were used as the quality control strains for the antifungal drug susceptibility testing.

3. Statistical Analysis

The $\chi^2$ test or the Fisher exact test were used for the categorical variables, and the student t test or Mann–Whitney U test were used for the continuous variables. All the significant tests were 2-tailed, with a $p$ value of less than 0.05 to be significant. We analyzed the impact of the initial treatment strategy on the primary outcome, with the predictors for clinical treatment failure assessed in the entire study population by using a backward stepwise logistic regression model.

For the secondary outcome, the follow-up period was until death or discharge from hospital to evaluate the variables related to death. A univariate logistic regression was fitted for each variable to test its relationship with the mortality outcomes. Variables that were clinically relevant and statistically significant ($p < 0.1$) on univariate analysis were enrolled into the multivariate regression model. Clinical interventions were maintained in the final model as a fixed variable. Potential confounders of the treatment strategies (NTISS score) were tested. We also ruled out significant interactions between the variables. Statistical analyses were performed using the SPSS, version 21.0 (IBM SPSS, Chicago, IL, USA).

4. Results

A total of 148 episodes of candidemia were identified during the study period. Among them, nine patients were excluded because the Candida species were unidentified in four cases and there were missing data from the hospital courses and/or final outcomes in five cases. Therefore, we enrolled a total of 139 episodes of candidemia in 123 neonates hospitalized in the NICUs of CGMH for analyses. The median (interquartile range, IQR) gestational age and birth weight of the neonates with candidemia were 29.0 (26.0–35.0) weeks and 1104.0 (762.0–2055) g, respectively. The median onset of candidemia in our cohort was 29.0 days old (IQR, 15.0–53.0 days), and there were seven episodes of early-onset sepsis (within the first week of life). Most of the patients had underlying chronic comorbidities, and more than one-third ($n = 47, 37.9\%$) had more than one comorbidity. The patient demographics of the study subjects are summarized in Table 1.

| Table 1. Patients’ demographics, microbiological characteristics, clinical features, and outcomes of 124 neonates with 139 episodes of candidemia in the neonatal intensive care unit of CGMH, 2003–2020. | No. (%) | No. (%) |
|---|---|---|
| **Patients’ demographics** (Total $n = 124$ Patients) | | Pathogens |
| Birth body weight (g), median (IQR) | 1104.0 (762.0–2055) | Candida albicans | 57 (41.0) |
| Gestational age (weeks), median (IQR) | 29.0 (26.0–35.0) | Candida parapsilosis | 44 (31.7) |
| Gender (male/female) | 75 (60.5)/49 (39.5) | Candida tropicalis | 5 (3.6) |
| NSD/Cesarean section | 60 (48.4)/64 (51.6) | Candida glabrata | 11 (7.9) |
| Inborn/outborn | 93 (75.0)/31 (25.0) | Candida guilliermondii | 12 (8.6) |
| 5 min Apgar score $\leq 7$, $n$ (%) | 52 (41.9) | Other Candida spp. | 10 (7.2) |
| Perinatal asphyxia, $n$ (%) | 8 (6.5) | Source of candidemia * | |
| Respiratory distress syndrome ($\geq$Gr II), $n$ (%) | 64 (51.6) | Primary bloodstream infection (BSI) | 92 (66.2) |
| Intraventricular hemorrhage ($\geq$Stage II), $n$ (%) | 28 (22.6) | Catheter-related BSI | 37 (26.6) |
| Day of life at onset of candidemia (day), median (IQR) | 26.0 (15.0–61.0) | Abdominal | 14 (10.1) |
### Table 1. Cont.

| Patients’ Characteristics (Total n = 124 Patients) | No. (%) | Microbiological Characteristics (Total n = 139 Episodes) | No. (%) |
|--------------------------------------------------|---------|----------------------------------------------------------|---------|
| Underlying Chronic Comorbidities, n (%)         |         | Urological                                               | 4 (2.9) |
| Neurological sequelae                            | 31 (25.0)| Pulmonary                                                | 7 (5.0) |
| Bronchopulmonary dysplasia                       | 70 (56.5)| Meningitis                                               | 3 (2.2) |
| Complicated cardiovascular diseases              | 6 (4.8)  | Clinical presentation                                    |         |
| Symptomatic patent ductus arteriosus             | 27 (21.8)| Sepsis                                                   | 112 (80.1) |
| Gastrointestinal sequelae                        | 31 (25.0)| Severe sepsis                                            | 77 (55.4) |
| Renal disorders                                  | 8 (6.4)  | Septic                                                  | 55 (39.6) |
| Congenital anomalies                             | 18 (14.5)| Progressive and deteriorated ¶                           | 41 (29.5) |
| Presences of any chronic comorbidities           | 103 (83.1)| Disseminated candidiasis §                                | 12 (8.6) |
| Presences of more than one comorbidities         | 47 (37.9)| Duration of candidemia, median (range)                  | 4.0 (1.0–42.0) |
| Case years                                       |         | Predisposing risk factors ¶                              |         |
| 2003–2006                                        | 33 (23.7)| Receipt of systemic antibiotics ¶                       | 129 (92.8) |
| 2007–2011                                        | 32 (23.0)| Previousazole exposure ¶                                | 22 (17.1) |
| 2012–2015                                        | 41 (29.5)| Prior bacteremia ¶                                      | 54 (38.8) |
| 2016–2020                                        | 33 (23.7)| Presence of CVC                                        | 133 (95.7) |
| 30-day, all-cause mortality (from the first episode) | 40 (32.3)| Receipt of parenteral nutrition                         | 130 (93.5) |
| Within 72 h without receiving antifungal therapy | 5 (4.0)  | Receipt of immunosuppressants                           | 4 (2.9) |
| Early mortality (>3 days, ≤7 days)               | 9 (7.3)  | Artificial device other than CVC                        | 42 (30.2) |
| Late mortality (8–30 days)                       | 26 (21.0)| Prior surgery ¶                                         | 45 (32.4) |
| Candidemia-attributable mortality                | 30 (24.2)| Neutropenia (ANC< 0.5×10^9/μL)                        | 11 (7.9) |
| Overall final in-hospital mortality              | 53 (42.7)| Persistent BSI ≥ 72 h after therapy                     | 52 (37.4) |
|                                                  |         | Clinical treatment failure                               | 47 (33.8) |

* Defined as the first sterile site where the fungal culture was positive, and sometimes multiple sources were identified in one candidemia episode. ¶ Defined as candidemia episodes with more disseminated candidiasis and/or progressive multi-organ failure even after effective antifungal agents. § Indicated the presence of underlying condition or risk factor at onset of *Candida* BSI, and most episodes occurred in patients with >1 underlying condition or risk factor. ¶ Within one month prior onset of candidemia. ¶ Indicated positive *Candida* isolates recovered from more than two sterile sites, in addition to primary bloodstream infection. BSI: bloodstream infection; ANC: absolute neutrophil count; CVC: central venous catheter; IQR: interquartile range; SD: standard deviation.

### 4.1. Microbiological Characteristics and Antifungal Susceptibility Results

Among all these candidemia episodes, there were two episodes in which two different *Candida* species were identified simultaneously on the same fungal culture. Mixed candidemia/bacteremia episodes were noted in 14 cases (10.1%), and Gram-negative rods were the most common bacterial pathogens (*n* = 9), followed by coagulase-negative staphylococci (*n* = 4) and other Gram-positive cocci (*n* = 1). Most of these episodes were primary bloodstream infections (*n* = 92, 66.2%) (Table 1). Forty-six point eight percent (*n* = 113) were susceptible to fluconazole (minimum inhibitory concentration [MIC] < 4 mg/L), although some uncommon *Candida* species have no standard MIC cut-off point of resistance. Specifically, two (3.5%) *C. albicans* isolates were resistant to fluconazole, but 100% of *C. glabrata* and 40.0% of *C. tropicalis* were intermediate or resistant to fluconazole. As we suspected, non-*albicans* Candida isolates had a significantly higher rate of azole resistance (*p < 0.01*). All *Candida* isolates were susceptible to amphoterocin B, and resistance to anidulafungin, caspofungin, and micafungin was uncommon: 2.3% for *C. parapsilosis* (*n* = 1), 9.1% for *C. glabrata* (*n* = 1), and no resistance among *C. albicans* and *C. tropicalis*. However, the MIC90 of echinocandins against *C. parapsilosis* and *C. glabrata* was higher than those recorded for the most common *Candida* species. Because of the
increasing trend of non-*albicans* candidemia during the study period and a significantly higher rate of antifungal resistance among non-*albicans* candida species, there was also an increasing trend ofazole-resistant candidemia during the study period.

**Figure 1.** The increasing trend of non-albicans candidemia in the neonatal intensive care unit of Chang Gung Memorial Hospital, 2004–2020.

**Table 2.** Minimum inhibitory concentration distributions of six antifungal agents to all Candida isolates that caused neonatal candidemia in the NICU of Chang Gung Memorial Hospital, 2003–2020.

| Pathogens/ Antifungals | No. of Isolates with MIC (mg/L) of: | MIC (mg/L) |
|-------------------------|-------------------------------------|------------|
|                         | 0.008 0.015 0.03 0.06 0.12 0.25 0.5 | 1.0 2.0 4.0 ≥8.0 GM MIC90 MIC90 |
| *Candida albicans* (total n = 57 tested) | Amphotericin B | 4 50 3 | 0.494 0.5 0.5 |
|                         | Fluconazole | 2 14 32 7 | 0.435 0.5 1 |
|                         | Voriconazole | 44 10 1 | 0.011 <0.008 0.005 |
|                         | Micafungin | 34 13 8 1 | 0.012 <0.008 0.03 |
|                         | Caspofungin | 2 9 40 5 1 | 0.056 0.06 0.12 |
|                         | Anidulafungin | 14 12 24 7 | 0.040 0.06 0.12 |
| *Candida parapsilosis* (total n = 44 tested) | Amphotericin B | 4 27 13 | 0.576 0.5 1.0 |
|                         | Fluconazole | 1 3 19 17 4 | 0.685 1.0 1.0 |
|                         | Voriconazole | 10 21 10 3 | 0.017 0.015 0.03 |
|                         | Micafungin | 1 7 25 10 1 | 0.999 1.0 2.0 |
|                         | Caspofungin | 1 3 27 11 2 | 0.585 0.5 1.0 |
|                         | Anidulafungin | 1 6 28 8 1 | 1.032 1.0 2.0 |
| *Candida glabrata* (total n = 11 tested) | Amphotericin B | 4 7 | 0.777 1.0 1.0 |
|                         | Fluconazole | 2 6 2 1 | 8.000 ≥8.0 ≥8.0 |
|                         | Voriconazole | 2 8 1 | 0.022 0.015 0.015 |
|                         | Micafungin | 1 3 1 | 0.137 0.12 0.12 |
|                         | Caspofungin | 1 2 7 | 0.057 0.03 0.06 |
|                         | Anidulafungin | 6 4 | 1 |
| *Candida tropicalis* (total n = 5 tested) | Amphotericin B | 1 4 | 0.871 1 1 |
|                         | Fluconazole | 2 2 1 | 2.639 2 8 |
|                         | Voriconazole | 2 2 1 | 0.214 0.25 0.25 |
|                         | Micafungin | 1 3 1 | 0.030 0.03 0.06 |
|                         | Caspofungin | 1 2 1 | 0.080 0.06 0.25 |
|                         | Anidulafungin | 1 1 2 1 | 0.092 0.12 0.25 |
| Other *Candida* spp. (total n = 22 tested) | Amphotericin B | 2 9 7 3 1 | 0.387 0.5 1.0 |
|                         | Fluconazole | 1 1 1 3 5 6 | 2.264 2 8 |
|                         | Voriconazole | 3 1 3 7 5 2 | 0.065 0.06 0.25 |
|                         | Micafungin | 3 1 2 1 5 | 0.192 0.25 1 |
|                         | Caspofungin | 2 3 3 9 4 1 | 0.204 0.25 0.5 |
|                         | Anidulafungin | 2 1 2 3 | 0.298 0.5 1 |

MIC: minimum inhibitory concentration. MIC90 and MIC90: MIC required to inhibit 50% and 90% of the isolates, respectively. GM: geometric mean.
4.2. Clinical Manifestations and Treatments

Among these candidemia episodes, 77 (55.4%) and 55 (39.6%) presented with severe sepsis and septic shock, respectively. After effective antifungal agents, 41 (29.5%) had a progressively deteriorated course, and 14 cases had persistent candidemia, which had positive Candida strains recovered from more than two consecutive fungal cultures after effective treatments. Four had an obstructing renal fungus ball and one had septic thrombophlebitis during the follow-up period. Blood cultures were persistently positive for more than 3 days in 37.4% of all the candidemia episodes.

The standard dosing of antifungal agents was prescribed in 134 (96.4%) of all the neonatal candidemia episodes, and there were five patients who did not receive any antifungal agents because all these patients died before the blood cultures of the Candida isolates were informed (Table 3). Fourteen point two percent were breakthrough candidemia; these patients were on antifungal prophylaxis when candidemia occurred. Antifungal therapy was initiated after a median of two days (range, 0–7), following the drawing of the first diagnostic blood culture. Of the 134 episodes with antifungal treatment, 39.6% (n = 55) had modification of the antifungal therapeutic agents, depending on the physicians’ decisions. The median duration of all therapeutic courses was 17.0 days (IQR, 14–24 days and range, 1–68).

Table 3. Therapeutic strategies of neonatal candidemia and comparisons of the C. albicans candidemia versus non-albicans candidemia.

| Variable | Overall (Total n = 139) | C. albicans Candidemia (Total n = 57) | Non-Albicans Candidemia (Total n = 82) | p Value ¶ |
|----------|-------------------------|--------------------------------------|----------------------------------------|--------|
| Final treatment regimens | 42 (30.2) | 16 (28.1) | 26 (31.7) | 0.870 |
| Fluconazole/Voriconazole | 57 (41.0) | 25 (43.9) | 32 (39.0) |  |
| Amphotericin B | 27 (19.4) | 10 (17.5) | 17 (20.7) |  |
| Echinocandin-based regimen | 7 (5.0) | 3 (5.3) | 4 (4.9) | 0.478 |
| Combination antifungal treatment | 5 (3.6) | 3 (5.3) | 2 (2.4) |  |
| No treatment | 55 (39.6) | 24 (42.1) | 31 (37.8) |  |
| Duration of antifungal treatment (d), median (IQR) | 17.0 (14.0–24.0) | 16.0 (14.0–22.0) | 18.0 (14.0–24.0) | 0.561 |
| Early removal of central venous catheter * | 50 (36.0) | 20 (35.1) | 30 (36.6) | 0.856 |
| Treatment outcomes | 48 (34.5) | 23 (40.4) | 25 (30.5) | 0.209 |
| Responsiveness after effective antifungals * | 20 (14.4) | 8 (14.0) | 12 (14.6) | 0.988 |
| 4–7 days | 24 (17.3) | 8 (14.0) | 16 (19.5) | 0.623 |
| More than 7 days | 47 (33.8) | 18 (31.6) | 29 (35.4) | 0.356 |
| Treatment failure | 4.0 (2.0–8.0) | 4.0 (1.0–7.0) | 4.0 (2.0–9.0) | 0.233 |

* Within the 3 days after onset of candidemia. ¶ p values were the comparison between neonatal episodes and non-neonatal episodes. * Responsiveness to antifungal agents was defined according to the consensus criteria of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer [26].

After the documentation of candidemia, the CVC was removed within 48 h and 72 h after obtaining the first positive blood cultures in 23.7% (33 of 139) and 36.0% (50 of 139) of the episodes, respectively. Neonatal candidemia with severe sepsis and septic shock was more likely to have delayed CVC removal (CVC removal performed after 72 h of onset) (80.5% vs. 43.6% and 80.0% vs. 53.6%, p < 0.001 and p = 0.002, respectively), which may be due to critically ill situations. After excluding five cases without any antifungal
treatments, 33.1% (n = 46) of the episodes of candidemia were treated with a catheter in situ, and the last 27.3% (n = 38) of the episodes had elective CVC removal. Among those with elective CVC removal, 21 (55.3%) of them had symptoms of candidemia, and clearance was resolved only after CVC removal.

4.3. Therapeutic Responses and Predictors of In-Hospital Mortality

Cumulative mortality at 7 and 30 days after the onset of candidemia was 11.4% (n = 14) and 32.3% (n = 40), respectively. Overall, the candidemia-attributable mortality rate was 24.2% (n = 30) and the in-hospital mortality rate for the neonates with candidemia was 42.7% (n = 52). The Kaplan–Meier method was used to compare the attributable mortality rates of sepsis caused by different pathogens in the NICU (Figure 2). Neonatal sepsis caused by Candida species had a significantly higher risk of overall mortality compared with other microorganisms (p < 0.01 by log rank test) (Figure 2). Although new antifungal agents were introduced in 2012, most therapeutic strategies have not changed in the past two decades, and the therapeutic outcomes were comparable between the four study periods (2003–2006, 2007–2011, 2012–2015, and 2016–2020).

Figure 2. Survival following positive blood culture from 124 neonates with candidemia and 713 neonates with late-onset sepsis in the NICU. The Kaplan–Meier graph is stratified by Gram-positive, Gram-negative organisms, and candida species. The y-axis is the proportion surviving.

Candidemia caused by non-albicans *Candida* species was previous reported to be associated with higher rates of antifungal resistance and treatment failure, but the differences of treatment were not observed in our cohort (Table 3). We identified the risk factors of treatment failure for neonatal candidemia using multivariate logistic regression (Supplemental Table S1). We found that delayed CVC removal (odds ratio [OR], 4.14; 95% confidence interval [CI]: 1.52–11.23, p = 0.005) and breakthrough candidemia (OR, 4.97; 95% CI: 1.80–13.7, p = 0.002) were independently associated with clinical treatment failure.

The independent risk factors of final in-hospital mortality in the neonates with candidemia were examined after excluding those without antifungal treatment. Gestational age, final antifungal treatment, and candida species were not independently associated with the final outcomes (Table 4). After multivariate analysis, the independent risk factors for in-hospital mortality in the neonates with candidemia were delayed catheter removal (odds ratio [OR], 5.54; 95% confidence interval [CI]: 1.93–15.86, p = 0.001), septic shock at the onset of candidemia (OR, 7.88; 95% CI: 2.83–21.93, p < 0.001), and multiple chronic comorbidities (OR, 8.71; 95% CI: 1.82–41.81, p = 0.007).
Table 4. Univariate and multivariate logistic regression analysis for independent risk factors of final in-hospital mortality in neonates with candidemia.

| Variables                          | Univariate Analyses | Multivariate Regression Analysis * |
|------------------------------------|---------------------|-----------------------------------|
|                                    | Odds Ratio          | 95% CI               | p Value # | Odds Ratio          | 95% CI               | p Value # |
| Gestational age                    |                     |                     |           |                     |                     |           |
| ≤27 weeks                          | 1.79                | 0.75–4.26           | 0.071     |                     |                     |           |
| 28–32 weeks                        | 0.39                | 0.14–1.09           | 0.190     |                     |                     |           |
| ≥33 weeks                          | 1 (reference)       |                     |           |                     |                     |           |
| Underlying chronic comorbidities   |                     |                     |           |                     |                     |           |
| No                                 | 1 (reference)       |                     |           | 1 (reference)       |                     |           |
| One                                | 2.84                | 0.74–10.9           | 0.128     | 3.63                | 0.77–17.01          | 0.102     |
| More than one chronic comorbidity  | 12.8                | 3.26–50.25          | <0.001    | 8.71                | 1.82–41.81          | 0.007     |
| Septic shock                       | 11.55               | 4.87–27.40          | <0.001    | 7.88                | 2.83–21.93          | <0.001    |
| Delayed CVC removal (>72 h)        | 6.48                | 2.67–15.69          | <0.001    | 5.54                | 1.93–15.86          | 0.001     |
| Subsequent bacteremia              | 1.53                | 0.75–3.13           | 0.244     |                     |                     |           |
| Breakthrough candidemia            | 3.17                | 1.10–9.12           | 0.032     | 0.97                | 0.24–4.06           | 0.974     |
| Delayed effective antifungal agents (>48 h) | 1.38                | 0.65–2.91           | 0.400     |                     |                     |           |
| Final antifungal therapy           |                     |                     |           |                     |                     |           |
| Fluconazole/Voriconazole           | 1 (reference)       |                     |           |                     |                     |           |
| Amphotericin B                     | 0.87                | 0.37–2.07           | 0.757     |                     |                     |           |
| Echinocandin-based regimen         | 1.75                | 0.62–4.95           | 0.295     |                     |                     |           |
| Combination regimens               | 3.20                | 0.52–19.67          | 0.209     |                     |                     |           |
| Pathogens                          |                     |                     |           |                     |                     |           |
| Candida albicans                   | 0.93                | 0.46–1.92           | 0.857     |                     |                     |           |
| Non-albicans Candida spp.          | 1.40                | 0.69–2.85           | 0.354     |                     |                     |           |
| Uncommon Candida spp.              |                     |                     |           |                     |                     |           |
| Case periods                        |                     |                     |           |                     |                     |           |
| 2003–2006                          | 1.63                | 0.60–4.41           | 0.335     |                     |                     |           |
| 2007–2011                          | 1.85                | 0.65–5.24           | 0.246     |                     |                     |           |
| 2012–2015                          | 0.86                | 0.30–2.50           | 0.787     |                     |                     |           |
| 2016–2020                          | 1 (reference)       |                     |           |                     |                     |           |

CI: confidence interval; CVC: central venous catheter. * For patients with more than two episodes of Candida bloodstream infection, data from the first episode of Candida bloodstream infection were enrolled into the model of multivariate analysis for predictors of final in-hospital mortality. # Hosmer–Lemeshow p = 0.649 and 0.427 for fungemia-attributable mortality and in-hospital mortality, respectively.

5. Discussion

Most of the current guidelines and the impacts of therapeutic strategies on the outcomes of invasive fungal infections are concluded from adult studies, patients with hematological malignancy, or surgical intensive care units [26,27]. There are relatively few data regarding neonatal candidemia, and the influences of illness severity, catheter removal, and the timing of antifungal therapy have not been well investigated [9,26,27]. We found that the treatment failure rate and final mortality rate among neonates remain high, especially in cases with underlying chronic comorbidities and catheter in situ. After multivariate analysis, we found delayed catheter removal, multiple chronic comorbidities, and septic shock at the onset were independently associated with final mortality among neonates with candidemia.

The in-hospital mortality and candidemia-attributable mortality rates of our cohort were relatively higher than previous studies, most of which reported a mortality rate of between 11.4% and 44%. The higher mortality rate in our cohort could be explained by the higher rates of severe sepsis and septic shock in our cohort. We have documented that the neonates with candidemia had a significantly higher rate of septic shock at the onset than late-onset sepsis caused by Gram-positive or even some Gram-negative pathogens [28]. Additionally, most of the neonates with candidemia had underlying chronic comorbidities, which has been documented to be the independent risk factor of the final adverse outcomes [28–30].

The issue of whether the CVC should be removed as early as possible after the occurrence of sepsis has been the topic of debate as most critically ill patients need the CVC for
antibiotic administration and fluid supplementation. Although there have been multicenter studies that did not reach a conclusion on the importance of early CVC removal to the outcomes [31–33], we did find that delayed CVC removal in neonates with candidemia was independently associated with final in-hospital mortality. This can probably be explained by these patients being more likely to have persistent candidemia and/or breakthrough candidemia, which is associated with final adverse outcomes [34,35]. However, in cases when the catheter is not the source of sepsis, it deserves a prospective, randomized controlled trial to document whether prompt catheter removal contributes significantly to the outcomes as it is often difficult to reinsert the CVC during the critically ill period. Because of different study designs, cohort selections, and perhaps the bias of illness severity, previous studies failed to have undebatable conclusions [31–33,36]. Nevertheless, we suggest that CVC removal at earliest stage of sepsis should be considered for neonates with candidemia, based on our study result and the current guidelines [37].

Initial treatment with echinocandin and anidulafungin have been found to be associated with better candidemia clearance and less likely treatment failure [20,38], but most of them were adult studies, and the results remain conflicting [20,38,39]. However, other studies did not support these results and found that the key to successfully treating candidemia would be adequate source control and appropriate antifungal agent administered in time [39,40]. In our cohort, we found that antifungal regimens did not have a significant influence on the treatment outcomes, whereas the final outcomes depended on the presences of chronic comorbidities and septic shock at the onset and whether the attending physician had early catheter removal. In our institute, echinocandins were rarely used as the initial treatment, and azoles remained the first-line antifungal agents because most Candida isolates were susceptible to fluconazole or amphotericin B. It is well known that the formation of biofilm will cause persistent candidemia [41], even though appropriate antifungal agents have been given. Therefore, we suggested that echinocandins or Amphotericin B should be considered as the therapeutic regimen, as the updated published European guidelines recommend [42], because these antifungal agents are effective in vitro against biofilms.

Different Candida species and the presences of chronic comorbidities could potentially affect the therapeutic response and the outcomes, as other studies have concluded [5,43]. Previous studies found that non-albicans Candida species were more likely to be antifungal resistant and potentially associated with a worse outcome [43–45], but this is not proven in this study. Among all the neonates with chronic comorbidities, the neonates with neurological sequelae and severe bronchopulmonary dysplasia with secondary pulmonary hypertension were most likely to have the worse outcomes, although the sample size in our cohort was inadequate to have significant statistical power. We found that these patients finally died of cardiopulmonary failure or another episode of clinical sepsis even though candidemia clearance was achieved. Recurrent sepsis in neonates has been documented to account for the high mortality rate in the NICU [46].

Only 14.5% of the Candida isolates in our cohort were azole resistant, which was relatively higher than other studies. However, there is an increasing trend of non-albicans candidemia in our cohort, especially after progressive antifungal prophylaxis since 2016 in our NICUs. Therefore, the azole-resistant rate of the Candida isolates has also been relatively higher since uncommon Candida species became more prevalent, and most of them were unsusceptible to fluconazole. Previous studies have also documented the increasing azole-resistant rate after routine antifungal prophylaxis [47,48]. We suggested that the policy of antifungal prophylaxis, especially among neonates of extremely low birth weight, should be judged based on more benefits than harm before clinical applications [14,49].

Some limitations need to be addressed in this study. Because of the single center and the retrospective study design, the conclusion of this study may be less applicable to other countries, where the epidemiological characteristics may be different. The case number of this cohort is relatively inadequate, and the study period extended for nearly two decades, during which time different therapeutic strategies may have affected the
outcomes. It is inevitable that the inadequate cases may preclude more subgroup analyses, such as specific non-albicans Candida species or antifungal-resistant Candida species as the pathogens. Additionally, serial follow-up blood culture was not performed systemically in most candidemia episodes, and the treatment strategies may be affected by the bias of a higher severity of illness.

In conclusion, we identified that delayed catheter removal, neonates with multiple chronic comorbidities, and septic shock were the most important predictors of final in-hospital mortality. The candidemia-attributable mortality in neonates remains high, perhaps due to a higher severity of illness and the delayed use of effective antifungal agents. The treatment outcomes have not changed or improved over the past decade, although new antifungal agents, such as caspofungin, have been launched in recent years. Therefore, prompt early catheter removal and aggressive therapeutic strategies for neonates with candidemia, especially for those with multiple chronic comorbidities or septic shock at the onset, will be very important to optimize the outcomes.

Supplementary Materials: The following are available online at: https://www.mdpi.com/article/10.3390/jof8050465/s1, Table S1. Univariate and multivariate logistic regression analysis of independent risk factors for clinical treatment failure.

Author Contributions: Conceptualization, Y.-N.C., J.-F.H., M.-H.T.; data collection and verification, J.-F.H., C.L., S.-M.C., H.-R.H., M.-C.C. and M.-Y.L.; formal analysis, J.-F.H., Y.-N.C. and C.L.; funding acquisition, J.-F.H. and P.-H.Y.; investigation, J.-F.H., H.-R.H. and C.L.; methodology, P.-H.Y., S.-M.C., H.-R.H. and M.-C.C.; supervision, J.-F.H. and M.-H.T.; writing—original draft, Y.-N.C. and J.-F.H.; writing—review and editing, M.-H.T. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant from the Ministry of Science and Technology in Taiwan (grant no. NMRPG3H0011 and MOST 107-2314-B-182A-005).

Institutional Review Board Statement: This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, with a waiver of informed consent because all patient records and information were anonymized and deidentified prior to analysis.

Informed Consent Statement: Patient consent was waived due to anonymous data collection.

Data Availability Statement: The datasets used/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: All authors thank Chiao-Ching Chiang for keeping the database of our NICU and all the nursing staff working in our NICUs for keeping extremely detailed patient records, which contributed greatly to the completion of this research.

Conflicts of Interest: The authors declare that they have no competing interest.

References

1. Walsh, T.J.; Katragkou, A.; Chen, T.; Salvatore, C.M.; Roilides, E. Invasive candidiasis in infants and children: Recent advances in epidemiology, diagnosis, and treatment. J. Fungi 2019, 5, 11. [CrossRef] [PubMed]

2. Lausch, K.R.; Schultz Dungu, K.H.; Callesen, M.T.; Schroder, H.; Sosthoj, S.; Foul sen, A.; Østergaard, L.; Mortensen, K.L.; Storgaard, M.; Schønheyder, H.C.; et al. Pediatric candidemia epidemiology and morbidity: A nationwide cohort. Pediatr. Infect. Dis. J. 2019, 38, 464–469. [CrossRef] [PubMed]

3. Piqueras, A.; Ganapathi, L.; Carpenter, J.; Rubio, T.; Sandora, T.; Flett, K.; Köhler, J. Trends in pediatric candidemia: Epidemiology, anti-fungal susceptibility, and patient characteristics in a Children’s hospital. J. Fungi 2021, 7, 78. [CrossRef] [PubMed]

4. Risum, M.; Astvad, K.; Johansen, H.; Schønheyder, H.; Rosenvinge, F.; Knudsen, J.; Hare, R.; Datcu, R.; Reder, B.; Antsupova, V.; et al. Update 2016-2018 of the nationwide Danish fungaemia surveillance study: Epidemiologic changes in a 15-year perspective. J. Fungi 2021, 7, 491. [CrossRef] [PubMed]

5. Warris, A.; Pana, Z.D.; Oletto, A.; Lundin, R.; Castagnola, E.; Lehrnbecher, T.; Groll, A.H.; Roilides, E. Etiology and outcome of candidemia in neonates and children in Europe: An 11-year multinational retrospective study. Pediatr. Infect. Dis. J. 2020, 39, 114–120. [CrossRef] [PubMed]

6. Fu, J.; Ding, Y.; Jiang, Y.; Mo, S.; Xu, S.; Qin, P. Persistent candidemia in very low birth weight neonates: Risk factors and clinical significance. BMC Infect. Dis. 2018, 18, 558. [CrossRef] [PubMed]
7. Kothalawala, M.; Jayaweera, J.A.A.S.; Arunan, S.; Jayathilake, A. The emergence of non-albicans candidemia and evaluation of HiChrome Candida differential agar and VITEK2 YST® platform for differentiation of Candida bloodstream isolates in teaching hospital Kandy, Sri Lanka. *BMC Microbiol.* 2019, 19, 136. [CrossRef]

8. Mantadakis, E.; Pana, Z.D.; Zaoutis, T. Candidemia in children: Epidemiology, prevention and management. *Mycoses* 2018, 61, 614–622. [CrossRef]

9. Benedict, K.; Roy, M.; Kabbani, S.; Anderson, E.J.; Farley, M.M.; Harb, S.; Harrison, L.H.; Bonner, L.; Wadu, V.L.; Marceaux, K.; et al. Neonatal and pediatric candidemia: Results from population-based active laboratory surveillance in four US locations, 2009–2015. *J. Pediatr. Infect. Dis. Soc.* 2018, 7, e78–e85. [CrossRef]

10. De Rose, D.U.; Santisi, A.; Ronchetti, M.P.; Martini, L.; Serafini, L.; Betta, P.; Maino, M.; Cavigioli, F.; Cocchi, I.; Pugni, L.; et al. Invasive *Candida* infections in neonates after major surgery: Current evidence and new directions. *Pathogens* 2021, 10, 319. [CrossRef]

11. Mohsin, J.; Weerakoon, S.; Ahmed, S.; Puts, Y.; Al Balushi, Z.; Meis, J.F.; Al-Hatmi, A. A cluster of *Candida auris* bloodstream infections in a tertiary care hospital in Oman from 2016 to 2019. *Antibiotics* 2020, 9, 638. [CrossRef] [PubMed]

12. Chen, I.T.; Chen, C.C.; Huang, H.C.; Kuo, K.C. Malassezia furfur emergence and candidemia trends in a neonatal intensive care unit during 10 years: The experience of fluconazole prophylaxis in a single hospital. *Adv. Neonatal. Care.* 2020, 20, E3–E8. [CrossRef] [PubMed]

13. Song, Y.; Chen, X.; Yan, Y.; Wan, Z.; Liu, W.; Li, R. Prevalence and antifungal susceptibility of pathogenic yeasts in China: A 10-year retrospective study in a Teaching hospital. *Front. Microbiol.* 2020, 11, 1401. [CrossRef] [PubMed]

14. Antolin, L.F.; Sharland, M.; Warris, A. Management of invasive fungal disease in neonates and children. *Pediatr. Infect. Dis. J.* 2019, 38 (Suppl. 1), S2–S6. [CrossRef]

15. Bassetti, M.; Garnacho-Montero, J.; Calandra, T.; Kullberg, B.; Dimopoulos, G.; Azoulay, E.; Chakrabarti, A.; Kett, D.; Leon, C.; Ostrosky-Zeichner, L.; et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. *Intensiv. Care Med.* 2017, 43, 1225–1238. [CrossRef]

16. Dudoignon, E.; Alanio, A.; Anstey, J.; Depret, F.; Coutrot, M.; Fratani, A.; Jully, M.; Cupaci, A.; Chauassard, M.; Oueslati, H.; et al. Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study. *Mycoses* 2019, 62, 237–246. [CrossRef]

17. Lai, M.-Y.; Hsu, J.-F.; Chu, S.-M.; Wu, I.-H.; Huang, H.-R.; Chiang, M.-C.; Fu, R.-H.; Tsai, M.-H. Risk factors and outcomes of recurrent candidemia in children: Relapse or re-infection? *J. Clin. Med.* 2019, 8, 99. [CrossRef]

18. Ala-Houhala, M.; Anttila, V. Characteristics of late recurrent candidemia in adult patients. *Mycoses* 2021, 64, 503–510. [CrossRef]

19. Reséndiz-Sánchez, J.; Ortiz-Alvarez, J.; Casimiro-Ramos, A.; Hernández, C.; Villa-Tanaca, L. First report of a catheter-related bloodstream infection by Candida haemulonii in a children’s hospital in Mexico City. *Int. J. Infect. Dis.* 2020, 92, 123–126. [CrossRef]

20. Lin, K.-Y.; Chen, P.-Y.; Chuang, Y.-C.; Wang, J.-T.; Sun, H.-Y.; Sheng, W.-H.; Chen, Y.-C.; Chang, S.-C. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis. *J. Infect.* 2018, 77, 224–248. [CrossRef]

21. Gray, J.E.; Richardson, D.K.; McCormick, M.C.; Workman-Daniels, K.; Goldmann, D.A. Neonatal therapeutic intervention scoring system: A therapy-based severity-of-illness index. *Pediatrics* 1992, 90, 561–567. [CrossRef] [PubMed]

22. Morin, L.; Ray, S.; Wilson, C.; Remy, S.; Benissa, M.R.; Jansen, N.J.G.; Javouhey, E.; Peters, M.; Kneyer, M.; Maclaren, G.; et al. Refractory septic shock in children: A European Society of Paediatric and Neonatal Intensive Care definition. *Intensiv. Care Med.* 2016, 42, 1948–1957. [CrossRef] [PubMed]

23. Donnelly, J.P.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and update of the consensus definitions of invasive fungal diseases from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research consortium. *Clin. Infect. Dis.* 2020, 71, 1367–1376. [CrossRef] [PubMed]

24. Orasch, C.; Marchetti, O.; Garbino, J.; Schrenzel, J.; Zimmerli, S.; Mühlethaler, K.; Pfäffler, G.; Ruef, C.; Fehr, J.; Zbinden, R.; et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: A 6-year prospective candidaemia survey from the fungal infection network of Switzerland. *Clin. Microbiol. Infect.* 2014, 20, 698–705. [CrossRef]

25. Arendrup, M.; Friberg, N.; Mares, M.; Kälhmer, G.; Meletiadis, J.; Guinea, J.; Andersen, C.; Arikian-Akdagli, S.; Barchiesi, F.; Chrysanthou, E.; et al. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). *Clin. Microbiol. Infect.* 2020, 26, 1464–1472. [CrossRef]

26. Warris, A.; Lehrnbecher, T.; Riolides, E.; Castagnola, E.; Bruggemann, R.J.M.; Groll, A.H. ESCMID-ECMM guideline: Diagnosis and management of invasive aspergillosis in neonates and children. *Clin. Microbiol. Infect.* 2019, 25, 1096–1113. [CrossRef]

27. Ferreras-Antolin, L.; Irwin, A.; Atra, A.; Chapelle, F.; Drysdale, S.B.; Emonts, M.; McMaster, P.; Paulus, S.; Patel, S.; Rompola, M.; et al. Pediatric antifungal prescribing patterns identify significant opportunities to rationalize antifungal use in children. *Pediatr. Infect. Dis. J.* 2022, 41, e69–e74. [CrossRef] [PubMed]

28. Tsai, M.H.; Hsu, J.F.; Chu, S.M.; Lien, R.; Huang, H.R.; Chiang, M.C.; Fu, R.H.; Lee, C.W.; Huang, Y.C. Incidence, clinical characteristics, and risk factors of adverse outcome in neonates with late-onset sepsis. *Pediatr. Infect. Dis. J.* 2014, 33, e7–e13. [CrossRef] [PubMed]
29. Hsu, J.-F.; Chu, S.-M.; Wang, H.-C.; Liao, C.-C.; Lai, M.-Y.; Huang, H.-R.; Chiang, M.-C.; Fu, R.-H.; Tsai, M.-H. Multidrug-resistant healthcare-associated infections in neonates with severe respiratory failure and the impacts of inappropriate initial antibiotic therapy. *Antibiotics* 2021, 10, 499. [CrossRef]

30. Tsai, M.-H.; Chu, S.-M.; Hsu, J.-F.; Lien, R.; Huang, H.-R.; Chiang, M.-C.; Fu, R.-H.; Lee, C.-W.; Huang, Y.-C. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. *Pediatrics* 2014, 133, e322–e329. [CrossRef]

31. Ford, W.J.; Bundy, D.G.; Oyeku, S.; Heo, M.; Saiman, L.; Rosenberg, R.E.; DeLaMora, P.; Rabin, B.; Zachariah, P.; Mirhaji, P.; et al. Central venous catheter salvage in ambulatory central line-associated bloodstream infections. *Pediatrics* 2021, 148, e2020042069. [CrossRef]

32. Janum, S.; Afshari, A. Central venous catheter (CVC) removal for patients of all ages with candidemia. *Cochrane Database Syst. Rev.* 2016, 7, CD011195. [PubMed]

33. McMullan, R.L.; Gordon, A. Antibiotics at the time of removal of central venous catheter to reduce morbidity and mortality in newborn infants. *Cochrane Database Syst. Rev.* 2018, 3, CD012181. [CrossRef] [PubMed]

34. Groll, A.H.; Pana, D.; Lanternier, F.; Mesini, A.; Ammann, A.R.; Averbuch, D.; Castagnola, E.; Cesaro, S.; Engelhard, D.; Garcia-Vidal, C.; et al. Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann. Hematol.* 2020, 100, 239–259. [CrossRef]

35. Ala-Houhala, M.; Anttila, V.J. Persistent vs. non-persistent candidemia in adult patients in 2007–2016: A retrospective cohort study. *Mycoses* 2020, 63, 617–624. [CrossRef]

36. Hecht, S.M.; Ardura, M.I.; Yildiz, V.O.; Ouellette, C.P. Central venous catheter management in high-risk children with bloodstream infections. *Pediatr. Infect. Dis. J.* 2020, 39, 17–22. [CrossRef]

37. Böll, B.; Schalk, E.; Buchheidt, D.; Hasenkamp, J.; Kiehl, M.; Kiderlen, T.R.; Kochanek, M.; Koldehoff, M.; Kostrewa, P.; Cläffen, A.Y.; et al. Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann. Hematol.* 2020, 100, 239–259. [CrossRef]

38. Lopez-Cortes, L.E.; Almirante, B.; Cuenca-Estrella, M.; Garnacho-Montero, J.; Padilla, B.; Puig-Asensio, M.; Ruiz-Camps, I.; Rodriguez-Baño, J. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: A propensity score-derived analysis of a population-based multicenter prospective cohort. *Clin. Microbiol. Infect.* 2016, 22, 733.e1–733.e8. [CrossRef]

39. Cuervo, G.; García-Vidal, C.; Puig-Asensio, M.; Vena, A.; Meije, Y.; Fernández-Ruiz, M.; Gonzalez-Barbera, E.M.; Blanco-Vidal, M.J.; Manzur, A.; Cardozo, C.; et al. Echinocandins compared to fluconazole for candidemia of a urinary tract source: A propensity score analysis. *Clin. Infect. Dis.* 2017, 64, 1374–1379. [CrossRef]

40. Agnelli, C.; on behalf of the COMIC Study Group (Collaborative Group on Mycosis); Valerio, M.; Bouza, E.; Vena, A.; Guine, J.; Martínez-Jiménez, M.D.C.; Marcos-Zambrano, L.J.; Escribano, P.; Muñoz, P. Persistent Candidaemia in adults: Underlying causes and clinical significance in the antifungal stewardship era. *Eur. J. Clin. Microbiol. Infect. Dis.* 2019, 38, 607–614. [CrossRef]

41. Li, W.-S.; Chen, Y.-C.; Kuo, S.-F.; Chen, F.-J.; Lee, C.-H. The impact of biofilm formation on the persistence of candidemia. *Front. Microbiol.* 2018, 9, 1196. [CrossRef] [PubMed]

42. Groll, A.H.; Pana, D.; Lanternier, F.; Mesini, A.; Ammann, A.R.; Averbuch, D.; Castagnola, E.; Cesarò, S.; Engelhard, D.; García-Vidal, C.; et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. *Lancet Oncol.* 2021, 22, e254–e269. [CrossRef]

43. Lee, W.-J.; Hsu, J.-F.; Lai, M.-Y.; Chiang, M.-C.; Lin, H.-C.; Huang, H.-R.; Wu, I.-H.; Chu, S.-M.; Fu, R.-H.; Tsai, M.-H. Factors and outcomes associated with candidemia caused by non-albicans *Candida* spp versus Candida albicans in children. *Am. J. Infect. Control* 2018, 46, 1387–1393. [CrossRef] [PubMed]

44. Ahmad, S.; Alfouzan, W. *Candida auris*: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. *Microorganism* 2021, 9, 807. [CrossRef] [PubMed]

45. Ko, J.-H.; Jung, D.S.; Lee, J.Y.; Kim, H.A.; Ryu, S.Y.; Jung, S.-I.; Joo, E.-J.; Cheon, S.; Kim, Y.-S.; Kim, S.-W.; et al. Poor prognosis of Candida tropicalis among non-albicans candidemia: A retrospective multicenter cohort study. *Korea. J. Clin. Microbiol. Infect. Dis.* 2019, 37, 195–200. [CrossRef]

46. Tsai, M.H.; Chu, S.M.; Lee, C.W.; Hsu, J.F.; Huang, H.R.; Chiang, M.C.; Fu, R.H.; Lien, R.; Huang, Y.C. Recurrent late-onset sepsis in the neonatal intensive care units: Incidence, clinical characteristics and risk factors. *Clin. Microbiol. Infect.* 2014, 20, O928–O935. [CrossRef]

47. Autmizguine, J.; Smith, P.B.; Prather, K.; Bendel, C.; Natarajan, G.; Bidegain, M.; Kaufman, A.D.; Burbridge, D.J.; Ross, A.S.; Pandit, P.; et al. Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. *J. Antimicrob. Chemother.* 2018, 73, 3482–3487. [CrossRef]

48. Lee, J.; Kim, H.S.; Shin, S.H.; Choi, C.W.; Kim, E.K.; Choi, E.H.; Kim, B.I.; Choi, J.-H. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: Multicenter pre-post cohort study. *BMC Pediatr.* 2016, 16, 67. [CrossRef]

49. Lehrnbecher, T.; Fisher, B.T.; Phillips, B.; Beauchemin, M.; Carlesse, F.; Castagnola, E.; Duong, N.; Dupuis, L.L.; Fioravanti, V.; Groll, A.H.; et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. *J. Clin. Oncol.* 2020, 38, 3205–3216. [CrossRef]